search
Back to results

Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia

Primary Purpose

Androgenic Alopecia

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
conditioned media of umbilical cord blood-derived stem cells
Placebo
Sponsored by
Medipost Co Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Androgenic Alopecia focused on measuring mesenchymal stem cells, conditioned media, NGF-574H, hair growth, androgenic alopecia, paracrine factors, umbilical cord blood

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Origin: Asian (Korean)
  2. Age: adult from 18 to 60 years old
  3. Sex: female (minimum 70) and male
  4. Understanding of the language spoken in the research center: subjects able to read the documents they are presented with and to hold to what they are explained.
  5. Social cover: subjects having medical coverage
  6. Subjects whose state of health, at the moment of inclusion, (auto-questionnaires and medical examinations for the recruitment, selection and inclusion), are compatible with this type of study.
  7. Subjects can be pursuit and observation during the study period.
  8. Subjects have a "hair loss grade" as below criteria:

    • BASP grade: Basic type (M2 to M3, or C2 to C3, or U1 to U3) or Specific type (V1 to V3, or F1 to F3)
    • For female: Ludwig grade: Ⅰ to Ⅱ
    • For male: Norwood-Hamilton grade: III to IV
    • Hair density by phototrichogram: 60 to 190 hair/cm2
    • Telogen hair ≥ 5%
  9. Subject with hair length ≥3cm in the vertex region and intending to keep this minimum length during the whole study period.
  10. Subject accepting the constraints of the phototrichogram technique, i.e. agreeing to have 1 shaved zone of 1.5cm2 on the scalp.
  11. Subject agreeing not to apply any topical treatment (other than the investigational product) or take any oral product or nutritional supplementation, or have any diet known to improve scalp and/or hair qualities or reduce hair loss during the whole study period.
  12. Subject agreeing to use a neutral shampoo (subject's own shampoo)
  13. Subject agrees to have a tattoo on the scalp on phototrichogram evaluation area.
  14. Subject presenting preferably with chestnut brown, dark or black hair (in order to avoid problems of contrast)

Exclusion Criteria:

  1. Subject deprived from liberty by a judiciary or administrative decision, sick subject in situation of emergency.
  2. Under age or off age subject protected by law, as well as those admitted to sanitary or social facilities, ever since the research can be performed in another manner.
  3. Subject who cannot be contacted in case of emergency.
  4. Females in pregnancy (positive urine pregnancy-tests performed at screening(visit 1 and visit 9)or nursing or without effective contraception method.
  5. Subject with any systemic disorder or skin disease (e.g. scalp disorders such as seborrheic dermatitis or scalp psoriasis) or presenting genetic or hormonal alopecia.
  6. Subject with a condition or receiving a medication which, in the opinion of the investigator, could compromise the safety of the subject or affect the outcome of the study.
  7. Subject using topic cosmetic treatment or oral nutritional supplement likely to interfere on hair loss parameters during the last 3 months prior to the start of the study (screening)
  8. Subject having a medical treatment likely to induce an alopecia or hypertrichosia, or having stopped it from than 3 months (including prostaglandins, rubefacients agents, all vasodilators, anti-androgens, all local hormonal treatment, etc...)
  9. Subject following a long period (>30 days) treatment of anti-inflammatory during the last 4 months before the start of the study (screening)
  10. Subject following a short period (<30 days) treatment of anti-inflammatory stopped or ongoing preceding the screening period.
  11. Subject having a immunosuppressive and/or corticoids treatment during the 4 weeks preceding the screening period
  12. Subject having dyed, bleached hair or with a permanent wave prior to study start.
  13. Subject who have been exposed to excessive or intensive UV light (natural or artificial) prior to the study.

Sites / Locations

  • Dankook University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

NGF-574H

placebo

Arm Description

NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss. NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.

Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.

Outcomes

Primary Outcome Measures

Change in mean total hair density (hair/cm2)
The hair density by phototrichogram for 24 weeks application, in comparison to initial value (baseline) and/or placebo product. Measurement of hair density by phototrichogram (Canfield): change in mean total hair density (hair/cm^2) Statistical analysis: Time and product effects (p<0.05)
Compare visual assessment before and after cosmetic treatment
Visual Assessment using the clinical picture by an investigator: 7 point score (-3 to 3) Visual assessment by a subject (Self-Assessment): 7 point score (-3 to 3)

Secondary Outcome Measures

Change in mean Telogen hair density
Measurement of telogen hair density, in comparison to initial value (baseline) and/or placebo product.
Change in mean Anagen hair density
Measurement of anagen hair density, in comparison to initial value (baseline) and/or placebo product.
Change in hair growth speed
Measurement of hair growth speed, in comparison to initial value (baseline) and/or placebo product.
Change in hair diameter
Measurement of hair diameter, in comparison to initial value (baseline) and/or placebo product. Measure hair diameter using electronic outside micrometer.

Full Information

First Posted
September 12, 2018
Last Updated
August 9, 2019
Sponsor
Medipost Co Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03676400
Brief Title
Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia
Official Title
Clinical Study for the Assessment of the Hair Growth Efficacy and Safety of a Cosmetic Investigational Product, After Repeated Applications for 24 Weeks, Under Normal Conditions of Use, in the Asian Adult Subjects With Androgenic Alopecia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
October 2, 2018 (Actual)
Primary Completion Date
July 22, 2019 (Actual)
Study Completion Date
July 24, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medipost Co Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to assess whether cosmetic investigational product containing NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.
Detailed Description
NGF-574H is a obtained by collection of paracrine factors secreted by human umbilical cord blood-derived mesenchymal stem cell that was exposed in vitro to an artificially designed environment mimicking alopecia state in hair follicles to prime the composition of the paracrine factors optimized for hair growth. This study is to assess and confirm whether NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Androgenic Alopecia
Keywords
mesenchymal stem cells, conditioned media, NGF-574H, hair growth, androgenic alopecia, paracrine factors, umbilical cord blood

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Product group / Control(placebo) group
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
84 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NGF-574H
Arm Type
Experimental
Arm Description
NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss. NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
Intervention Type
Other
Intervention Name(s)
conditioned media of umbilical cord blood-derived stem cells
Other Intervention Name(s)
NGF-574H
Intervention Description
Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
Primary Outcome Measure Information:
Title
Change in mean total hair density (hair/cm2)
Description
The hair density by phototrichogram for 24 weeks application, in comparison to initial value (baseline) and/or placebo product. Measurement of hair density by phototrichogram (Canfield): change in mean total hair density (hair/cm^2) Statistical analysis: Time and product effects (p<0.05)
Time Frame
0, 6, 12 and 24 weeks
Title
Compare visual assessment before and after cosmetic treatment
Description
Visual Assessment using the clinical picture by an investigator: 7 point score (-3 to 3) Visual assessment by a subject (Self-Assessment): 7 point score (-3 to 3)
Time Frame
0, 6, 12 and 24 weeks
Secondary Outcome Measure Information:
Title
Change in mean Telogen hair density
Description
Measurement of telogen hair density, in comparison to initial value (baseline) and/or placebo product.
Time Frame
0, 6, 12 and 24 weeks
Title
Change in mean Anagen hair density
Description
Measurement of anagen hair density, in comparison to initial value (baseline) and/or placebo product.
Time Frame
0, 6, 12 and 24 weeks
Title
Change in hair growth speed
Description
Measurement of hair growth speed, in comparison to initial value (baseline) and/or placebo product.
Time Frame
0, 6, 12 and 24 weeks
Title
Change in hair diameter
Description
Measurement of hair diameter, in comparison to initial value (baseline) and/or placebo product. Measure hair diameter using electronic outside micrometer.
Time Frame
0, 6, 12 and 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Origin: Asian (Korean) Age: adult from 18 to 60 years old Sex: female (minimum 70) and male Understanding of the language spoken in the research center: subjects able to read the documents they are presented with and to hold to what they are explained. Social cover: subjects having medical coverage Subjects whose state of health, at the moment of inclusion, (auto-questionnaires and medical examinations for the recruitment, selection and inclusion), are compatible with this type of study. Subjects can be pursuit and observation during the study period. Subjects have a "hair loss grade" as below criteria: BASP grade: Basic type (M2 to M3, or C2 to C3, or U1 to U3) or Specific type (V1 to V3, or F1 to F3) For female: Ludwig grade: Ⅰ to Ⅱ For male: Norwood-Hamilton grade: III to IV Hair density by phototrichogram: 60 to 190 hair/cm2 Telogen hair ≥ 5% Subject with hair length ≥3cm in the vertex region and intending to keep this minimum length during the whole study period. Subject accepting the constraints of the phototrichogram technique, i.e. agreeing to have 1 shaved zone of 1.5cm2 on the scalp. Subject agreeing not to apply any topical treatment (other than the investigational product) or take any oral product or nutritional supplementation, or have any diet known to improve scalp and/or hair qualities or reduce hair loss during the whole study period. Subject agreeing to use a neutral shampoo (subject's own shampoo) Subject agrees to have a tattoo on the scalp on phototrichogram evaluation area. Subject presenting preferably with chestnut brown, dark or black hair (in order to avoid problems of contrast) Exclusion Criteria: Subject deprived from liberty by a judiciary or administrative decision, sick subject in situation of emergency. Under age or off age subject protected by law, as well as those admitted to sanitary or social facilities, ever since the research can be performed in another manner. Subject who cannot be contacted in case of emergency. Females in pregnancy (positive urine pregnancy-tests performed at screening(visit 1 and visit 9)or nursing or without effective contraception method. Subject with any systemic disorder or skin disease (e.g. scalp disorders such as seborrheic dermatitis or scalp psoriasis) or presenting genetic or hormonal alopecia. Subject with a condition or receiving a medication which, in the opinion of the investigator, could compromise the safety of the subject or affect the outcome of the study. Subject using topic cosmetic treatment or oral nutritional supplement likely to interfere on hair loss parameters during the last 3 months prior to the start of the study (screening) Subject having a medical treatment likely to induce an alopecia or hypertrichosia, or having stopped it from than 3 months (including prostaglandins, rubefacients agents, all vasodilators, anti-androgens, all local hormonal treatment, etc...) Subject following a long period (>30 days) treatment of anti-inflammatory during the last 4 months before the start of the study (screening) Subject following a short period (<30 days) treatment of anti-inflammatory stopped or ongoing preceding the screening period. Subject having a immunosuppressive and/or corticoids treatment during the 4 weeks preceding the screening period Subject having dyed, bleached hair or with a permanent wave prior to study start. Subject who have been exposed to excessive or intensive UV light (natural or artificial) prior to the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Byungcheol PARK, MD
Organizational Affiliation
Dankook University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dankook University Hospital
City
Cheonan
State/Province
Chung Nam
ZIP/Postal Code
31116
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia

We'll reach out to this number within 24 hrs